| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10752622 | Biochemical and Biophysical Research Communications | 2015 | 5 Pages |
Abstract
ULK1 acts to inhibit S6k1 phosphorylation at T389, leading to MN9D viability reduction under MPP+ treatment. These results provide evidence for a novel mechanism by which the ULK1 inhibit S6k1 T389 phosphorylation contributes to neurodegeneration in MPP+ treated-MN9D, and suggests a new therapeutic strategy for PD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Yongle Li, Jun Zhang, Chunxiang Yang,